Investigational drug · Phase 2
PBGM01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "PBGM01"
First trial start
2021
Mar 17, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PBGM01", any sponsor or status.
Conditions studied
As listed on its trial records.
- GM1 Gangliosidosis
- GM1 Gangliosidosis, Type I
- GM1 Gangliosidosis, Type 2
- Beta-Galactosidase-1 (GLB1) Deficiency
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "PBGM01" as an intervention, largest first.
- Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 GangliosidosisActive, not recruiting
Gemma BiotherapeuticsIndustry
NCT04713475 · 26 participants (planned) · Start Mar 17, 2021 · Primary completion Feb 2028
Drug: PBGM01 · For: GM1 Gangliosidosis; GM1 Gangliosidosis, Type I; GM1 Gangliosidosis, Type 2 and 1 more
Sites: Oakland, California; Minneapolis, Minnesota; New Brunswick, New Jersey · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for GM1 Gangliosidosis
- NizubaglustatAZ-3102Phase 36 trials
Azafaros B.V. · Niemann-Pick Type C Disease, GM2 Gangliosidosis, GM1 Gangliosidosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.